Literature DB >> 6409946

Analysis of the complexity of the multimeric structure of factor VIII related antigen/von Willebrand protein using a modified electrophoretic technique.

M S Enayat, F G Hill.   

Abstract

A method for multimeric analysis of factor VIII related antigen/von Willebrand protein is described. By modifying an existing method the technique has been simplified and optimised so that the different molecular forms of factor VIII related antigen and their triplet structure can be visualised. Clear differences can be seen between patterns in normals and type IIA von Willebrand's disease variants in that the latter lack high and intermediate multimers and also have a different configuration to the triplet pattern in the lower molecular weight multimers. Differences in triplet pattern can also be seen in different type IIA patients. The advantages and further application of this method for investigating the molecular defect in von Willebrand's disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6409946      PMCID: PMC498421          DOI: 10.1136/jcp.36.8.915

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  19 in total

1.  Comparison of factor VIII-related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate.

Authors:  M Weinstein; D Deykin
Journal:  Blood       Date:  1979-06       Impact factor: 22.113

2.  The iodination of follicle-stimulating and other hormones for radioimmunoassay.

Authors:  W R Butt
Journal:  J Endocrinol       Date:  1972-11       Impact factor: 4.286

3.  Porcine Willebrand factor: a population of multimers.

Authors:  D N Fass; G J Knutson; E J Bowie
Journal:  J Lab Clin Med       Date:  1978-02

4.  Isolation and characterization of human Factor VIII (antihemophilic factor).

Authors:  M E Legaz; G Schmer; R B Counts; E W Davie
Journal:  J Biol Chem       Date:  1973-06-10       Impact factor: 5.157

5.  Factor VIII, a series of homologous oligomers and a complex of two proteins.

Authors:  J A van Mourik; B N Bouma; W T LaBruyère; S de Graaf; I A Mochtar
Journal:  Thromb Res       Date:  1974-01       Impact factor: 3.944

6.  Isolation and some chemical properties of human factor VIII (antihemophilic factor).

Authors:  E J Hershgold; A M Davison; M E Janszen
Journal:  J Lab Clin Med       Date:  1971-02

7.  Studies on factor VIII-related protein. I. Ultrastructural and electrophoretic heterogeneity of human factor VIII-related protein.

Authors:  E A Beck; L Tranqui-Pouit; A Chapel; B A Perret; M Furlan; G Hudry-Clergeon; M Suscillon
Journal:  Biochim Biophys Acta       Date:  1979-05-23

8.  Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII oligomers.

Authors:  B A Perret; M Furlan; E A Beck
Journal:  Biochim Biophys Acta       Date:  1979-05-23

9.  Studies on the purification and characterization of human factor 8.

Authors:  S L Marchesi; N R Shulman; H R Gralnick
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

10.  Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease.

Authors:  D Meyer; B Obert; G Pietu; J M Lavergne; T S Zimmerman
Journal:  J Lab Clin Med       Date:  1980-04
View more
  10 in total

1.  Acquired von Willebrand's disease and hypothyroidism: report of a case presenting with menorrhagia.

Authors:  N E Blesing; H Hambley; G A McDonald
Journal:  Postgrad Med J       Date:  1990-06       Impact factor: 2.401

2.  Changes in the factor VIII complex in diabetic ketoacidosis: evidence of endothelial cell damage?

Authors:  M Greaves; C Pickering; G Knight; A J Boulton; J Ball; J D Ward; F E Preston
Journal:  Diabetologia       Date:  1987-03       Impact factor: 10.122

3.  Analysis of von Willebrand factor multimers using a commercially available enhanced chemiluminescence kit.

Authors:  A M Cumming; R T Wensley
Journal:  J Clin Pathol       Date:  1993-05       Impact factor: 3.411

4.  Abnormalities of factor VIII related protein multimers in the haemolytic uraemic syndrome.

Authors:  P E Rose; S M Enayat; R Sunderland; P E Short; C E Williams; F G Hill
Journal:  Arch Dis Child       Date:  1984-12       Impact factor: 3.791

5.  Simultaneous inheritance and expression of classical haemophilia A and type IIA von Willebrand's disease.

Authors:  A C Beddall; S M Enayat; C E Williams; P E Short; F G Hill
Journal:  J Clin Pathol       Date:  1984-09       Impact factor: 3.411

6.  Lack of correlation between factor VIII related antigen multimeric analysis pattern and parallel or non-parallel dose response curves in an ELISA factor VIII related antigen assay.

Authors:  P E Short; C E Williams; M S Enayat; A M Picken; F G Hill
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

7.  Investigation of a kindred with a new autosomal dominantly inherited variant type von Willebrand's disease (possible type IID).

Authors:  F G Hill; M S Enayat; A J George
Journal:  J Clin Pathol       Date:  1985-06       Impact factor: 3.411

8.  In vitro correction of the abnormal multimeric structure of von Willebrand factor in type IIa von Willebrand's disease.

Authors:  H R Gralnick; S B Williams; L P McKeown; P Maisonneuve; C Jenneau; Y Sultan; M E Rick
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

9.  Characterization of Von Willebrand Factor Multimer Structure in Patients With Severe Aortic Stenosis.

Authors:  Joerg Kellermair; Helmut W Ott; Michael Spannagl; Josef Tomasits; Juergen Kammler; Hermann Blessberger; Christian Reiter; Clemens Steinwender
Journal:  Clin Appl Thromb Hemost       Date:  2017-12-04       Impact factor: 2.389

10.  Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers.

Authors:  Annette E Bowyer; Karen J Goodfellow; Holger Seidel; Philipp Westhofen; Francesca Stufano; Anne Goodeve; Stephen Kitchen; Michael Makris
Journal:  Res Pract Thromb Haemost       Date:  2018-08-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.